# Effect of Dapagliflozin on Microvascular and Macrovascular Circulation and Total Body Sodium Content

> **NCT02383238** · PHASE3 · COMPLETED · sponsor: **University of Erlangen-Nürnberg Medical School** · enrollment: 59 (actual)

## Conditions studied

- Diabetes Mellitus Type 2

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02383238
- **Lead sponsor:** University of Erlangen-Nürnberg Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2018-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02383238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02383238, "Effect of Dapagliflozin on Microvascular and Macrovascular Circulation and Total Body Sodium Content". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02383238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*